drugset
drugset / Trial / NCT01935960

Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers

NCT01935960 ↗

Phase 1 Completed 40 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase I trial studies the side effects and best dose of retinoid 9cUAB30 in preventing cancer in healthy volunteers. The use of retinoid 9cUAB30 may keep cancer from forming in healthy volunteers.

Timeline

Start
2013-08
Primary completion
2016-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject UAB30 Other / unclassified — Oral

Indications

No indication recorded.